Live price temporarily unavailable.
Rapid Micro Biosystems (RPID) is a Information Technology company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $16.1M | $23.2M | $17.1M | $22.5M | $28.1M | $33.6M |
| Growth (year over year) | — | +44.5% | −26.3% | +31.4% | +24.6% | +19.7% |
| Operating income | −$30.5M | −$47.2M | −$63.2M | −$56.6M | −$49.9M | −$47.4M |
| Operating margin | −190.0% | −203.3% | −369.0% | −251.2% | −178.0% | −141.1% |
| Net income | −$37.1M | −$73.5M | −$60.8M | −$52.5M | −$46.9M | −$47.1M |
| Net margin | −230.6% | −316.5% | −354.9% | −233.0% | −167.2% | −140.3% |
| EPS (diluted) | −$126.11 | −$3.94 | −$1.43 | −$1.22 | −$1.08 | −$1.05 |
| Balance sheet | ||||||
| Cash and equivalents | $30.1M | $178.4M | $27.1M | $24.3M | $16.9M | $20.0M |
| Total assets | $70.0M | $241.2M | $190.7M | $143.5M | $98.2M | $74.9M |
| Total liabilities | $45.2M | $20.2M | $26.5M | $25.5M | $22.8M | $41.6M |
| Long-term debt | $24.8M | $0 | $0 | — | $0 | $18.9M |
| Shareholders' equity | −$127.0M | $221.0M | $164.2M | $118.0M | $75.4M | $33.2M |
| Cash flow | ||||||
| Operating cash flow | −$31.0M | −$55.0M | −$58.5M | −$45.1M | −$44.2M | −$31.1M |
| Capital expenditure | $690.0K | $3.22M | $6.74M | $1.84M | $1.36M | $850.0K |
| Free cash flow | −$31.7M | −$58.2M | −$65.3M | −$46.9M | −$45.5M | −$31.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.60M | $8.22M | $7.21M | $7.26M | $7.84M | $11.3M | $8.00M | $8.05M |
| Growth (year over year) | +23.7% | +29.7% | +28.4% | +9.7% | +3.1% | +37.3% | +11.1% | +10.9% |
| Gross profit | — | — | $404.0K | $275.0K | — | — | $371.0K | $1.21M |
| Gross margin | — | — | 5.6% | 3.8% | — | — | 4.6% | 15.0% |
| Operating income | −$12.0M | −$10.2M | −$11.7M | −$12.1M | −$11.4M | −$12.2M | −$13.9M | −$12.3M |
| Operating margin | −158.3% | −124.5% | −161.8% | −167.3% | −145.1% | −108.2% | −173.1% | −153.0% |
| Net income | −$11.3M | −$9.67M | −$11.3M | −$11.9M | −$11.5M | −$12.5M | −$14.3M | −$12.9M |
| Net margin | −148.9% | −117.6% | −156.3% | −163.3% | −146.8% | −110.8% | −178.4% | −160.5% |
| EPS (diluted) | −$0.26 | −$0.22 | −$0.26 | −$0.27 | −$0.26 | −$0.26 | −$0.31 | −$0.27 |
| Balance sheet | ||||||||
| Cash and equivalents | $22.0M | $16.9M | $18.9M | $18.3M | $18.9M | $20.0M | $13.8M | $14.7M |
| Total assets | $105.8M | $98.2M | $85.4M | $75.6M | $84.4M | $74.9M | $62.4M | $58.5M |
| Total liabilities | $21.5M | $22.8M | $19.9M | $21.0M | $40.1M | $41.6M | $42.0M | $40.7M |
| Long-term debt | — | $0 | — | — | $18.8M | $18.9M | $19.1M | $19.1M |
| Shareholders' equity | $84.4M | $75.4M | $65.5M | $54.5M | $44.3M | $33.2M | $20.4M | $17.7M |
| Cash flow | ||||||||
| Operating cash flow | −$8.60M | −$9.91M | −$9.06M | −$9.70M | −$9.05M | −$3.25M | −$15.1M | −$12.7M |
| Capital expenditure | $223.0K | $98.0K | $319.0K | $366.0K | $73.0K | $92.0K | $394.0K | −$223.0K |
| Free cash flow | −$8.82M | −$10.0M | −$9.38M | −$10.1M | −$9.12M | −$3.34M | −$15.5M | −$12.5M |
From Rapid Micro Biosystems's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Rapid Micro Biosystems in our feed yet.